IntegriChain, a provider of data-driven commercialisation solutions for the pharmaceutical industry, has acquired pharma advisory and managed services firm Federal Compliance Solutions (FCS).
The move creates a comprehensive team of experts in government pricing and payer/provider contracting, responding to the growing trend of outsourcing in pharma and addressing significant commercial and regulatory changes.
Go deeper with GlobalData
The acquisition involved IntegriChain taking over the equity of FCS.
FCS’ entire team will join IntegriChain’s global workforce, which now stands at 750.
The collaboration between IntegriChain and FCS is set to enhance their combined portfolio of solutions and services, tackling complex challenges such as complicated drug contracting, the expansion of the 340B programme, the Inflation Reduction Act’s implications for pricing and reimbursement, and the evolving nature of drug distribution channels.
FCS managing partner Rick Moore stated: “IntegriChain has established itself as a proven data and technology innovator, combining forces with others to create a leading net revenue management outsourcing and consulting capability.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“We are excited to join IntegriChain’s family and platform and look forward to our combined teams continuing to partner with Pharma manufacturers of all sizes and types and driving innovation in contracts and pricing, and gross-to-net.”
The acquisition marks IntegriChain’s seventh expansion.
Fairmount Partners served as the exclusive financial advisor to FCS during the transaction.
By 2025, the merged entity intends to integrate advisory services and business-process-as-a-service offerings into IntegriChain’s ICyte platform.
IntegriChain CEO Josh Halpern stated: “As drug pricing and reimbursement have grown increasingly complicated, more and more pharma manufacturers have embraced outsourcing options where service providers perform price calculations and adjudicate rebates and chargebacks on their behalf.
